Skip to main content

ELAN

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

ELAN Price
Price Chart

Forward-looking statistics

Beta
1.23
Risk
42.13%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees9K
Market cap$9.0B

Fundamentals

Enterprise value$11.0B
Revenue$4.4B
Revenue per employee—
Profit margin8.43%
Debt to equity69.18

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$0.75
Dividend per share—
Revenue per share$8.95
Avg trading volume (30 day)$82M
Avg trading volume (10 day)$74M
Put-call ratio—

Macro factor sensitivity

Growth+0.7
Credit+4.6
Liquidity-0.9
Inflation-2.5
Commodities-0.0
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio15.57
Price to sales1.64
P/E Ratio15.57
Enterprise Value to Revenue2.48
Price to book1.14

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.

Benzinga (June 26, 2025)
What Makes Elanco Animal Health (ELAN) a New Buy Stock

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (June 10, 2025)
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco

Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.

CNBC Television (April 23, 2025)
Elanco's President & CEO on Zenrelia Approved by FDA

Jeff Sessions, Elanco Animal Health President & CEO speak with Alix Steel and Vonnie Quinn about new pet drug Zenrelia being approved by the FDA. -------- More on Bloomberg Television and Markets Like this video?

Bloomberg Markets and Finance (September 20, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free